Published in Health Business Week, November 18th, 2005
The new Pharmacor report, "Strategic Overview of the Dementia Drug Market 2004-2014," forecasts that by 2014 Alzhemed and Flurizan, the first disease-modifying treatments for dementia, will account for 57% of drug sales in this market.
The report also finds that sales of acetylcholinesterase inhibitors including Eisai/Pfizer's Aricept,...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health Business Week